Literature DB >> 8283503

Cochlear implants and otitis media: considerations in two cleft palate patients.

L S Parnes1, J P Gagne, R Hassan.   

Abstract

Cochlear implantation is a safe and effective means of rehabilitating profound sensory deafness. The implications of coincident chronic middle ear disease upon the operative procedure and auditory results have received little attention in the literature. We describe two patients, each with congenital cleft lip and palate and secondary chronic otitis media with effusion, who received multichannel cochlear implants following bacterial meningitis. One patient (a three-year-old girl) was implanted in the standard fashion while the other (a 38-year-old-man) underwent middle ear and mastoid obliteration. Our findings suggest that chronic otitis media should not be a deterrent to cochlear implantation.

Entities:  

Mesh:

Year:  1993        PMID: 8283503

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  4 in total

1.  Cochlear implantation in patients with chronic otitis: indications for subtotal petrosectomy and obliteration of the middle ear.

Authors:  P R Issing; M P Schönermark; S Winkelmann; H G Kempf; A Ernst
Journal:  Skull Base Surg       Date:  1998

2.  Cochlear implantation in chronic otitis media and previous middle ear surgery: 20 years of experience.

Authors:  V Vincenti; E Pasanisi; A Bacciu; S Bacciu; C Zini
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-08       Impact factor: 2.124

3.  Subtotal Petrosectomy in Cochlear Implant Surgery: Our Experience.

Authors:  Rahul Kurkure; Pabina Rayamajhi; Ashish Castellino; Sandhya Dharmarajan; Ruchima Dham; Kiran Natarajan; Mohan Kameswaran
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-02-12

4.  Long-term outcome of cochlear implant in patients with chronic otitis media: one-stage surgery is equivalent to two-stage surgery.

Authors:  Jeong Hun Jang; Min-Hyun Park; Jae-Jin Song; Jun Ho Lee; Seung Ha Oh; Chong-Sun Kim; Sun O Chang
Journal:  J Korean Med Sci       Date:  2014-12-23       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.